Ascendis Pharma A/S (NASDAQ:ASND) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report report published on Thursday, Benzinga reports. Cantor Fitzgerald currently has a $173.00 target price on the biotechnology company’s stock.

Other equities analysts have also issued reports about the stock. StockNews.com upgraded shares of Ascendis Pharma A/S from a sell rating to a hold rating in a research report on Monday, December 25th. Citigroup lifted their price objective on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a buy rating in a research report on Thursday, February 8th. JPMorgan Chase & Co. lifted their price objective on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an overweight rating in a research report on Tuesday, April 2nd. Wells Fargo & Company lifted their price objective on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the company an overweight rating in a research report on Friday, March 15th. Finally, Jefferies Financial Group started coverage on shares of Ascendis Pharma A/S in a research report on Wednesday, December 20th. They issued a buy rating and a $150.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Ascendis Pharma A/S has an average rating of Moderate Buy and an average price target of $173.25.

Ascendis Pharma A/S Trading Down 0.9 %

ASND stock opened at $140.89 on Thursday. Ascendis Pharma A/S has a twelve month low of $66.03 and a twelve month high of $161.00. The company’s 50 day moving average is $149.20 and its two-hundred day moving average is $123.87. The stock has a market cap of $8.20 billion, a P/E ratio of -15.23 and a beta of 0.50.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.15) by $0.49. The company had revenue of $148.62 million for the quarter, compared to analysts’ expectations of $97.02 million. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. On average, equities research analysts predict that Ascendis Pharma A/S will post -4.19 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. US Bancorp DE raised its stake in Ascendis Pharma A/S by 35.2% in the 4th quarter. US Bancorp DE now owns 284 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 74 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in Ascendis Pharma A/S by 37.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 91 shares during the last quarter. GAMMA Investing LLC raised its stake in Ascendis Pharma A/S by 52.0% in the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 102 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in Ascendis Pharma A/S by 3.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 3,226 shares of the biotechnology company’s stock valued at $333,000 after purchasing an additional 105 shares during the last quarter. Finally, Guggenheim Capital LLC raised its stake in Ascendis Pharma A/S by 7.2% in the 1st quarter. Guggenheim Capital LLC now owns 2,008 shares of the biotechnology company’s stock valued at $236,000 after purchasing an additional 135 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.